Neurocrine Biosciences has received FDA approval for CRENESSITY™ (crinecerfont), the first of its kind therapy for both children and adults suffering from classic congenital adrenal hyperplasia.
In the Phase 3 PATINA trial, Pfizer's IBRANCE® combined with standard treatments improved median progression-free survival by more than 15 months in patients.
Candel Therapeutics reports that CAN-2409 met its main goal in a Phase 3 trial for prostate cancer, demonstrating a notable increase in disease-free survival.
Caliway reports positive outcomes from CBL-0204, a Phase 2b trial of CBL-514 aimed at decreasing abdominal subcutaneous fat, achieving all key efficacy goals.